tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Promising Outlook for 4D Molecular Therapeutics: Buy Rating Backed by Strategic Partnerships and Strong Financial Position
PremiumRatingsPromising Outlook for 4D Molecular Therapeutics: Buy Rating Backed by Strategic Partnerships and Strong Financial Position
1M ago
4D Molecular price target raised to $32 from $26 at RBC Capital
Premium
The Fly
4D Molecular price target raised to $32 from $26 at RBC Capital
1M ago
4D Molecular price target lowered to $33 from $38 at Barclays
Premium
The Fly
4D Molecular price target lowered to $33 from $38 at Barclays
2M ago
Bullish Outlook on 4D Molecular Therapeutics’ 4D-150: Promising Long-term Efficacy, Safety, and Financial Strength Justify Buy Rating
PremiumRatingsBullish Outlook on 4D Molecular Therapeutics’ 4D-150: Promising Long-term Efficacy, Safety, and Financial Strength Justify Buy Rating
2M ago
4D Molecular upgraded to Equal Weight from Underweight at Morgan Stanley
Premium
The Fly
4D Molecular upgraded to Equal Weight from Underweight at Morgan Stanley
2M ago
4D Molecular’s 4D-150 shows efficacy in Phase 1/2 wet AMD trial
Premium
The Fly
4D Molecular’s 4D-150 shows efficacy in Phase 1/2 wet AMD trial
2M ago
4D Molecular Therapeutics Advances in Macular Degeneration Treatment: A Phase 3 Study Update
PremiumCompany Announcements4D Molecular Therapeutics Advances in Macular Degeneration Treatment: A Phase 3 Study Update
2M ago
4D Molecular Therapeutics Advances Gene Therapy for Wet AMD
Premium
Company Announcements
4D Molecular Therapeutics Advances Gene Therapy for Wet AMD
2M ago
4D Molecular Therapeutics Advances Gene Therapy Trial for Cystic Fibrosis
Premium
Company Announcements
4D Molecular Therapeutics Advances Gene Therapy Trial for Cystic Fibrosis
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100